Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164113 | 0.92 | MTNR1B (0.37) | FAAHMTNR1BHDAC1HDAC2HDAC3 | |
| SCHEMBL5543247 | 0.77 | MTNR1B (0.37) | FAAHMTNR1BCCNE2CDK4CCND1 | |
| SCHEMBL5672243 | 0.77 | MTNR1B (0.37) | FAAHMTNR1BCCNE2CDK4CCND1 | |
| SCHEMBL24258932 | 0.75 | FAAH (0.35) | FAAHMTNR1BHDAC1HDAC2HDAC3 | |
| SCHEMBL12128445 | 0.74 | — | — | |
| SCHEMBL22352802 | 0.74 | HDAC1 (0.45) | FAAHMTNR1BHDAC1HDAC2HDAC3 | |
| SCHEMBL21894059 | 0.72 | — | — | |
| SCHEMBL24259167 | 0.69 | MAPT (0.47) | MTNR1BMAPTMTNR1ALMNAPGR | |
| SCHEMBL12125441 | 0.69 | SORT1 (0.42) | TLR7MTNR1BCCNE2CDK4CCND1 | |
| SCHEMBL17032192 | 0.69 | NUDT1 (0.40) | MTNR1BCCNE2CDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | FAAH 2934/4885TLR7 449/4885MTNR1B 679/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | FAAH 2934/4885TLR7 449/4885MTNR1B 679/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | FAAH 2505/4885TLR7 227/4885MTNR1B 560/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | FAAH 2934/4885TLR7 449/4885MTNR1B 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.